In conclusion, YTHDC1 mitigates MASLD by inhibiting the PTPN22-mediated dephosphorylation and activation of NLRP3, offering new insights into therapeutic strategies for MASLD. The gene discussed is NLRP3; the disease is metabolic dysfunction-associated steatotic liver disease.